- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07949955
Hot Water Immersion on Fluid Overload in People With End-stage Kidney Disease (ESRD and HWI)
The Effect of Repeated Hot Water Immersion on Fluid Overload, Sweat Loss, Cardiovascular Function and Quality of Life in People With End-stage Kidney Disease on Haemodialysis.
Dialysis is important in treating people with end-stage kidney disease (ESKD) to remove excess water and toxins, maintaining quality of life (QoL) and to keep people alive. Where people with ESKD retain too much water (fluid overload), the amount of water removed and the speed of removal must be higher to meet the individual's needs and avoid short- and long-term negative consequences. This can be a particular issue for people on haemodialysis after a weekend, when there is a 2-day gap between dialysis sessions. Removing the larger quantities of water quickly (proportional to speed of removal) can lead to low blood pressure, reducing QoL and increasing the chance of getting heart and blood vessel disease and the risk of death. Additionally, the dialysis schedules, and lack of dialysis capacity, often means sessions cannot be extended, or patients are offered extra sessions for fluid removal. Given the need to reduce fluid overload and the difficulties people have sticking to fluid restrictions, (taken by mouth) other therapies are needed to improve outcomes and people's experiences.
One such possible therapy is to induce sweating via passive heating (i.e. sitting in hot tubs). Few studies have examined sweat loss rates with heating in people with ESKD. Given the potential cost-effective method for reducing excessive body water and improving QoL, there is little evidence with no data examining any associated cardiovascular or quality of life benefits.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Chronic kidney disease (CKD) affects ~10% of people worldwide and is characterised by progressive deterioration of renal function, which leads to increased morbidity and mortality. As CKD progresses, loss of renal function reduces sodium filtration, suppresses tubular reabsorption of electrolytes and results in fluid volume expansion that can lead to fluid overload. Fluid overload has numerous signs and symptoms, including oedema, shortness of breath, fatigue and hypertension. Fluid removal is critical in the treatment of CKD because fluid overload increases the risk of congestive heart failure, left ventricular hypertrophy and other cardiovascular sequelae and increased mortality. Current treatments include sodium restriction, diuretics, fluid restriction, lifestyle modifications, including alcohol restriction, weight management, exercise prescription. When people reach end-stage renal disease (ESRD), the kidneys no longer effectively remove toxins and manage fluid homeostasis. If a transplant is not available, then people are reliant on ultrafiltration on dialysis (either haemodialysis or peritoneal dialysis) to remain euvolaemic. Many of these treatments (especially for in-centre haemodialysis) have low levels of adherence and have a major impact on quality of life [21-24]. Moreover, large volume mechanical ultrafiltration and the rate of ultrafiltration on haemodialysis associates with cardiac functional changes directly linked to peoples outcomes. This is particularly relevant due to inflexible dialysis schedules (4 hours x 3 times weekly) and lack of dialysis capacity; it is not always feasible to reduce the rate of ultrafiltration either by extending the session or offering an extra session. Exploring adjunct treatments to manage fluid overload to improve patient outcomes and experience are warranted.
Dialysis is critical in the management of ESRD to keep people alive and to maintain quality of life (QoL). In people with fluid overload there is a particular need for higher ultrafiltration volumes (and rates) (i.e. fluid removal via dialysis) to maintain dry weight (i.e. mass without fluid overload) to reduce the risk of acute and chronic adverse events. This can be a particular issue for people on haemodialysis after the long 2-day gap. However, large ultrafiltration volumes and increased UF rates can lead to intradialytic hypotension (IDH), dizziness, nausea, headaches and cramping. Importantly, IDH increases the risk of cardiovascular disease and all-cause mortality and is linked to myocardial stunning events that are driven by large volume ultrafiltration. Given the need to reduce fluid overload and the difficulties patients have sticking to fluid restrictions exploration of alternative therapies is warranted.
One such possible therapy is to induce fluid loss via sweating via passive heating. Commonly administered through hot water immersion (HWI), this limits evaporative heat loss to the areas not immersed and, in conjunction with the high thermal conductivity of water, rapidly increases deep body temperature, ultimately leading to increased sweating. Multiple studies have shown sweat loss rates of ~1L‧h-1 with passive heating in healthy people, whilst in individuals with CKD sweat loss is ~0.6-0.8 L‧h-1. Given the potential cost-effective method for reducing fluid overload, there is a paucity of evidence on induced diaphoresis in people with CKD. Modalities of heating that have been used in people with CKD include; exercise, saunas and bath tubs with no data examining any associated metabolic, cardiovascular or quality of life benefits.
Passive heating has also been linked to improvements in metabolic and cardiovascular function by both intra and extracellular mechanisms. We recently reported that 8-10 HWIs within a 14-day period improves fasting insulin sensitivity, plasma [insulin], cardiac output, stroke volume and blood pressure (BP) in individuals with Type 2 Diabetes Mellitus (T2DM). Whilst other groups report similar findings on metabolic and cardiovascular function in healthy individuals and other clinical cohorts. Passive heating increases the cellular protective chaperones known as heat shock proteins (HSP) which may in part explain some of these beneficial effec ts. Passive heating increases [HSP72] (in skeletal muscle), [HSP70] and [HSP27], which reduces inflammatory transcription factors, upregulate glutathione redox cycle and increases endothelial nitric oxide synthase.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Daniel Piccolo, PhD
- Telefonnummer: +44
- E-post: daniel.piccolo@port.ac.uk
Studer Kontakt Backup
- Navn: Ant I Shepherd, PhD
- Telefonnummer: 5289 +44239284
- E-post: ant.shepherd@port.ac.uk
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or Female, aged 16 years or above.
- Diagnosed with ESRD of any aetiology
- Undergoing in centre haemodialysis treatment three times weekly for 4 hours per session
- Has been on HD for at least 6 months
- Is not on immunosuppression
- Participant is willing and able to give informed consent for participation in the study.
Exclusion Criteria:
- Severe peripheral neuropathy (to the point where they cannot sense temperature).
- Skin ulcerations
- Eczema
- Pre-existing postural hypotension
- Uncontrolled hypertension (≥180 systolic / 100 diastolic mmHg).
- Taking any medication which may interfere with data interpretation or safety
- Taking any oral immunosuppressive medication (excluding prednisolone up to 5mg) or having had intravenous immunosuppressive agents (cyclophosphamide, rituximab, or similar) in the 6 months preceding the start of the study
- Any other serious medical condition which would interfere with data interpretation or safety will be excluded from participation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Hot water immersion
Daily passive heating: Participants will attend the laboratory on 4 occasions within a period of 7 days (~ 90 min per visit) at any point in the day (standardised within participant). Anyone completing less than 3 sessions will be excluded from analysis. During each visit participants will self-insert a rectal thermistor (shown to a private room and given instruction) and will then be immersed into a hot tub (~ 40 oC) for 60 min. Body position will be manipulated as required to achieve and maintain a target Trec at 38.5-39.0oC using 40oC water. Participants will be required to wear a bathing suit and a t-shirt for all heating visits. |
Daily passive heating: Participants will attend the laboratory on 4 occasions within a period of 7 days (~ 90 min per visit) at any point in the day (standardised within participant). Anyone completing less than 3 sessions will be excluded from analysis. During each visit participants will self-insert a rectal thermistor (shown to a private room and given instruction) and will then be immersed into a hot tub (~ 40 oC) for 60 min. Body position will be manipulated as required to achieve and maintain a target Trec at 38.5-39.0oC using 40oC water. Participants will be required to wear a bathing suit and a t-shirt for all heating visits. |
|
Ingen inngripen: Control
Participants in this arm will receive usual care, consisting of standard clinical management provided as part of routine healthcare practice. No additional intervention will be administered by the study team. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Interdialytic Weight Gain (IDWG):
Tidsramme: through study completion, average 1 week
|
IDWG will be calculated for each dialysis session and will be computed as the difference between the persons pre-dialysis weight and their post-dialysis weight ( IDWG= current pre dialysis weight - previous post dialysis weight). These values will then be averaged to produce the weekly IDWG estimate. |
through study completion, average 1 week
|
|
Deviation from Dry Weight:
Tidsramme: through study completion, average 1 week
|
Over the same one-week time frame, the average difference between the post-dialysis weight and the prescribed dry weight will be calculated for all dialysis sessions. This metric reflects the persons achievement of euvolemia at the end of treatment. Positive values indicate residual fluid excess, while negative values indicate post-dialysis weight below the targeted dry weight. |
through study completion, average 1 week
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Weight
Tidsramme: through study completion, average 1 week
|
Sweat loss will be recorded for each hot tub immersion. Immediately prior to immersion and immediately after immersion following be towel dried. Both assessments are done nude whilst de-instrumented. Any |
through study completion, average 1 week
|
|
Quality of Life - Kidney Disease Quality of Life Instrument
Tidsramme: through study completion, average 1 week
|
The Kidney Disease Quality of Life Instrument (KDQoL-36) scale has been shown to have high reliability and validity [53]. The KDQoL is freely available at https://www.rand.org/health/surveys/kdqol.html and contains 24 questions. |
through study completion, average 1 week
|
|
Quality of life - World Health Organisation quality of life (WHOQOL-BREF).
Tidsramme: through study completion, average 1 week
|
The WHOQOL-BREF is a 26-item self-report questionnaire developed by the World Health Organization to assess an individual's perceived quality of life, and has been shown to have high reliability and validity [54]. The WHOQOL-BREF is freely available at https://www.who.int/tools/whoqol/whoqol-bref. |
through study completion, average 1 week
|
|
Systolic blood pressure
Tidsramme: through study completion, average 1 week
|
Resting systolic blood pressure will be measured five times and recorded as the average of the final three measurements. |
through study completion, average 1 week
|
|
Diastolic blood pressure
Tidsramme: through study completion, average 1 week
|
Resting diastolic blood pressure will be measured five times and recorded as the average of the final three measurements |
through study completion, average 1 week
|
|
Mean arterial pressure
Tidsramme: through study completion, average 1 week
|
Resting mean arterial pressure will be measured five times and recorded as the average of the final three measurements |
through study completion, average 1 week
|
|
cardiac output
Tidsramme: through study completion, average 1 week
|
Using thoracic bio-reactance technology (Physioflow), which will derive cardiac output at rest. Six electrodes are placed on the participant's chest and neck between which a small, painless current is passed. |
through study completion, average 1 week
|
|
Macrovascular function
Tidsramme: through study completion, average 1 week
|
rachial artery FMD will be used as a measure of endothelial function [69]. Endothelial-dependent function is assessed by measuring FMD in response to a 5 minute ischaemic stimulus, induced by forearm cuff inflation [69]. Measurements will be performed in the supine position on the right arm (if fistula is present, technique will be run on left arm) with the cuff placed distal to the olecranon process. High-resolution duplex ultrasound (Terason uSmart 3300, Teratech, Burlington, MA) with a 15.0-4.0-MHz linear wideband array probe will be used to image the brachial artery at the distal third of the upper arm and simultaneously record the longitudinal B-mode image and Doppler blood velocity trace. The angle of Doppler insonation will be 60°. |
through study completion, average 1 week
|
|
Assessment of inferior vena cava
Tidsramme: through study completion, average 1 week
|
Assessing diameter and collapsibility with inspiration can provide an indirect assessment of central venous (right atrial) pressure. Using a standard, low-frequency (ultrasound) probe the IVC diameter in M-mode is measured approximately 1-2 cm distal to the junction of the hepatic vein and the right atrium. The diameter is measured during expiration (maximum) and during inspiration (sniff, minimum). |
through study completion, average 1 week
|
|
Microvascular function
Tidsramme: through study completion, average 1 week
|
Individuals will be acclimated for a minimum of 30 minutes in an ambient temperature of 23 ºC prior to acetylcholine (ACh) and sodium nitroprusside (SNP) being delivered transdermally via iontophoresis to volar aspect of the left forearm. |
through study completion, average 1 week
|
|
Cognitive performance
Tidsramme: through study completion, average 1 week
|
Cognitive performance will be assessed using a four-task cognitive battery administered on a laptop computer using commercially available testing software (ANAM: Automated Neurophysiological Assessment Metrics, developed for the US Department of Defence and licensed by Vista Life Sciences). For each task, scoring will be based on accuracy and/or response time. Completion of the test requires the participant to use a normal computer mouse, which has been deemed a suitable method to test cognitive function in older adults (Zygouris & Tsolaki, 2015). Participants will be familiarised with the ANAM software, where they will complete the testing battery 3-5 times until their performance has plateaued. The ANAM software manual states that the programme has test-retest reliability for over one year, therefore participants will not need to be refamiliarised with the software before their final experimental visit. |
through study completion, average 1 week
|
|
Interviews
Tidsramme: through study completion, average 1 week
|
Qualitative sub-studies will explore study feasibility, acceptability, and participants' overall experiences. In terms of the acceptability, the study will explore it based on the Theoretical Framework of Acceptability [55]. It will explore participants affective attitudes towards the intervention, the burden the intervention might be to the participants, the perceived effectiveness and the user experience of the intervention, the intention of the participants to take part in the intervention. The interviews will take place during the fourth visit irrespective of the intervention sequence. |
through study completion, average 1 week
|
|
Total body water:
Tidsramme: through study completion, average 1 week
|
Total body water content will be assessed via bioelectrical impedance using a single-frequency hand-to-foot device (Bodystat 1500, Bodystat Ltd., Douglas, Isle of Man, United Kingdom). The participants' height, age, sex, weight, frame size, and activity level will first be inputted to the device. Participants will then lie supine on a bed with legs slightly apart and arms at an approximate 30° angle to the body. Four adhesive electrodes will be attached to the dorsal surfaces of the right hand and right foot. Prior to electrode placement, the four placement sites will be cleaned with an alcohol swab. Participants will be instructed to lie completely still while the measurement is taken. |
through study completion, average 1 week
|
|
Perceptual measures of heat stress:
Tidsramme: through study completion, average 1 week
|
Thermal comfort and sensation scales will be used during the investigation to provide a subjective rating of how the participants are feeling within the environment. For thermal comfort participants will be asked to rate their perception of satisfaction of the environment from their state of mind. For thermal sensation, participants will be asked to rate their perception of the sensory feeling of the environment around them. Both questions will be measured on a six-point and six-point scale respectively. This will provide a more in detail understanding of the sensory and state of mind of thermal perception. Participants will be provided with a pen and will be asked to draw a line onto the scale regarding their answer. This will then be measured on a visual analogue scale, and be recorded in cm (Stevens et al., 2025). The marker location will be taken as the uppermost and leftmost extent of the ink marking drawn by participants. |
through study completion, average 1 week
|
|
plasma [Troponin]
Tidsramme: through study completion, average 1 week
|
A sample will be drawn at each specified visit/time point into a single 10 mL ethylenediaminetetraacetic acid (EDTA) tube (K2, BD, USA) for analysis of plasma [Troponin] |
through study completion, average 1 week
|
|
plasma [NTproBNP]
Tidsramme: through study completion, average 1 week
|
A sample will be drawn at each specified visit/time point into a single 10 mL ethylenediaminetetraacetic acid (EDTA) tube (K2, BD, USA) for analysis of plasma [NTproBNP] |
through study completion, average 1 week
|
|
plasma [HSP70].
Tidsramme: through study completion, average 1 week
|
A sample will be drawn at each specified visit/time point into a single 10 mL ethylenediaminetetraacetic acid (EDTA) tube (K2, BD, USA) for analysis of plasma [HSP70]. |
through study completion, average 1 week
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ant Shepherd, PhD, University of Portsmouth
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Patologiske prosesser
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Kronisk sykdom
- Sykdomsattributter
- Nyreinsuffisiens
- Nyresvikt, kronisk
- Patologiske tilstander, tegn og symptomer
- Nyresvikt, kronisk
Andre studie-ID-numre
- 373138
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .